Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
- PMID: 15464447
- DOI: 10.1016/j.molmed.2004.08.008
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
Abstract
The epidermal growth factor receptor (EGFR) gene product is a receptor tyrosine kinase (TK) that affects many important downstream pathways. The recent finding that mutations in EGFR predict the response of lung cancers to therapies that target the TK domain of the gene product has generated considerable interest. The mutations are associated with adenocarcinoma histology, oriental origin, female gender and never-smoker status. Most mutations target structures in the TK domain that appear to be essential for the phosphorylation function of the gene. Cancer cells with mutant EGFR genes might become physiologically dependent on the continued activity of the gene for the maintenance of their malignant phenotype; however, this might also be a target for therapy.
Similar articles
-
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.Cancer Res. 2005 Mar 1;65(5):1642-6. doi: 10.1158/0008-5472.CAN-04-4235. Cancer Res. 2005. PMID: 15753357
-
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.Cancer Res. 2004 Dec 15;64(24):8919-23. doi: 10.1158/0008-5472.CAN-04-2818. Cancer Res. 2004. PMID: 15604253
-
EGFR and erbB2 mutation status in Japanese lung cancer patients.Int J Cancer. 2006 Jan 1;118(1):180-4. doi: 10.1002/ijc.21301. Int J Cancer. 2006. PMID: 16003726
-
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.Int J Cancer. 2006 Jan 15;118(2):257-62. doi: 10.1002/ijc.21496. Int J Cancer. 2006. PMID: 16231326 Review.
-
Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.Cancer Metastasis Rev. 2010 Mar;29(1):49-60. doi: 10.1007/s10555-010-9209-4. Cancer Metastasis Rev. 2010. PMID: 20108024 Review.
Cited by
-
Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance.Sci Rep. 2016 May 6;6:25468. doi: 10.1038/srep25468. Sci Rep. 2016. PMID: 27151505 Free PMC article.
-
NCI's provocative questions on cancer: some answers to ignite discussion.Oncotarget. 2011 Dec;2(12):1352-67. doi: 10.18632/oncotarget.432. Oncotarget. 2011. PMID: 22267462 Free PMC article.
-
N-glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC.Cancer Sci. 2021 May;112(5):1911-1923. doi: 10.1111/cas.14872. Epub 2021 Mar 30. Cancer Sci. 2021. PMID: 33706413 Free PMC article.
-
gcMECM: graph clustering of mutual exclusivity of cancer mutations.BMC Bioinformatics. 2021 Dec 14;22(1):592. doi: 10.1186/s12859-021-04505-w. BMC Bioinformatics. 2021. PMID: 34906079 Free PMC article.
-
The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.J Mol Histol. 2014 Dec;45(6):641-52. doi: 10.1007/s10735-014-9583-2. Epub 2014 Jul 10. J Mol Histol. 2014. PMID: 25008024
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
